Case series reports survival following fosmanogepix salvage therapy in pediatric rhino-orbital-cerebral mucormycosis, highlighting its promise for refractory fungal infections.
Key Points
To report the clinical outcomes and safety of expanded access fosmanogepix in pediatric patients with severe, treatment-refractory rhino-orbital-cerebral mucormycosis.
Assessed two pediatric patients presenting with diabetic ketoacidosis and extensive rhino-orbital-cerebral mucormycosis.
Administered investigational fosmanogepix under expanded access after multimodal standard therapy (liposomal amphotericin B, micafungin, and azoles) failed to clear infection.
Both patients demonstrated clinical improvement following the addition of fosmanogepix, allowing the discontinuation of more poorly tolerated antifungals.
Both patients completed several months of fosmanogepix therapy, tolerated the medication well, and survived the infection.